Venture capital is heavily backing companies with AI-powered drug discovery engines. Irindil Labs' massive $787 million financing shows extreme investor confidence that computational platforms can de-risk and accelerate pipeline development for complex diseases like autoimmune disorders and cancer.
Major players are repurposing oncology's T-cell engager technology for autoimmune diseases. Gilead's $1.675B acquisition of Oral Medicines and Sanofi's $1.05B potential deal with Kali Therapeutics highlight a strategic shift to leverage this powerful modality in a new, high-potential therapeutic area.
The metabolic disease market is seeing intense innovation beyond standard injectables. Structure Therapeutics' oral GLP-1 agonist showed efficacy comparable to injections in Phase 2, while Novo Nordisk's triple agonist demonstrated superior results to semaglutide, signaling a multi-pronged assault on current market leaders.
Major firms like Merck employ varied deal structures to build pipelines. Merck's $6.7 billion all-upfront acquisition of Terns for a Phase 1-2 asset contrasts with its Quotient collaboration, which has a small $20 million upfront but $2.2 billion in discovery-stage milestones. This highlights a flexible approach to risk and reward.